Molecular Response (MRL) Announced Today the Appointment of Cyrus K. Mirsaidi to Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the appointment of Cyrus K. Mirsaidi to Chief Executive Officer.

Mr. Mirsaidi will be focused on fostering strategic partnerships, continuing development of the company’s intellectual property, and growing Molecular Response into a successful molecular diagnostic service company. Dr. Masood Tayebi will continue to serve as Molecular Response’s Executive Chairman and continue to support growth of the company through his dynamic leadership.

“We are glad to have Cyrus, a strong leader in the diagnostic industry, join the Molecular Response Team as CEO,” said Chairman, Dr. Masood Tayebi. “We are focusing on getting the right therapeutic to the right patient by developing diagnostics that support revolutionary therapeutic treatments. Through his leadership I am positive we can make a difference in the treatment of debilitating diseases like cancer.”

Mr. Mirsaidi brings both practical and strategic senior management experience in drug discovery, biomarker development, and clinical diagnostics. He held several senior level management positions in his ten-year career at Nichols Institute Diagnostics (a division of Quest Diagnostics), where he was responsible for global launch of clinical diagnostic IVD tests and automated platforms. As general manager and executive director at Ontogen, a small molecule discovery company, he managed operations of a subsidiary focused on high throughput synthesis and purification of novel compounds. Most recently, Mr. Mirsaidi served as Vice President at AltheaDx, a San Diego biotechnology company, where he led the business development and licensing efforts with pharmaceutical partners.

“I am pleased to lead Molecular Response Laboratories in this period of expansion and change. MRL has already secured several exclusive assets, that I will announce in the coming weeks,” said Mirsaidi. “I look forward to building MRL into a leading molecular diagnostic company with focus on building exclusive collaborations and partnerships that can truly make a difference in how patients, like many of our loved ones, are screened, treated, and monitored.”

About Molecular Response

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and increase the efficacy of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs; our results reduce risk and improve the success rate of drugs in development and allow for the most informed decisions with best chance of success to advance therapeutic programs.

For additional information, please visit

Contacts Molecular Response John Cox, Public Relations 858-622-2931

Back to news